As part of a restructuring effort, Seres Therapeutics, a Cambridge, Mass.-based drugmaker developing biological treatments, will cut 30 percent of its workforce and make changes to its executive team.
The layoffs will affect about 30 positions in research, manufacturing and administrative services.
David Cook, PhD, the company's executive vice president and chief scientific officer, will step down from his role. Dr. Cook will continue to provide consulting services.
Matthew Henn, PhD, previously Seres' executive vice president and head of discovery and microbiome R&D, has been appointed chief scientific officer.
"A number of valued employees will be departing Seres as a part of these corporate changes, and I want to deeply thank each of them for their important contributions to the company. I would like to specifically recognize David Cook, who has had a tremendous impact advancing Seres' research activities as well as more broadly on the strategic direction of the company," said Eric Shaff, president and CEO of Seres.
The changes are to help Seres focus resources on the highest priority, clinical stage therapy candidates, the company said.